Get the Daily Brief
Latest Biotech News
NervGen’s NVG‑291 shows durable gains in chronic spinal cord injury
NervGen released expanded CONNECT‑SCI data showing durable functional improvements out to week 16 and in blinded exit interviews up to 364 days for NVG‑291 in chronic spinal cord injury patients....
Tempus picks up OneOme pharmacogenetics assets after OneOme collapse
Tempus confirmed acquisition of pharmacogenetics assets from OneOme, the Mayo Clinic spin‑out that recently dissolved amid financial difficulties. Tempus said the deal includes OneOme’s RightMed...
Plasmidsaurus launches ultra‑fast, low‑cost RNA‑seq service – cores uneasy
Plasmidsaurus introduced a shallow‑depth RNA‑seq transcriptome service promising 2–3 day turnaround and $50 per academic sample, claiming it can replace qPCR and other targeted assays. The company...
Africa CDC launches AGARI: continent‑wide pathogen genomics hub
The Africa Centres for Disease Control and Prevention unveiled AGARI (Africa Genome Archiving for Response and Insight), a secure genomic data platform co‑developed with member states to archive,...
Cellarity unveils ToxPredictor: AI model flags drug‑induced liver injury
Cellarity published validation of ToxPredictor, an AI toxicogenomics model built on DILImap—transcriptomic signatures from primary human hepatocytes exposed to 300 DILI‑linked compounds. The firm...
FDA probes Takeda’s Adzynma after pediatric death, neutralizing antibodies reported
The U.S. Food and Drug Administration opened an investigation into Takeda’s Adzynma after reports that treated patients developed neutralizing antibodies and a pediatric death that ‘‘appears to be...
Semaglutide misses in pivotal Alzheimer’s test — Novo setback
Novo Nordisk reported that two large Phase III trials testing oral semaglutide (Rybelsus) failed to slow cognitive decline in patients with early symptomatic Alzheimer’s disease and confirmed...
Bayer’s asundexian meets stroke endpoint — FXIa hopes revive
Bayer announced that its oral Factor XIa inhibitor asundexian met the primary endpoint in the Oceanic Stroke Phase III trial, reducing recurrent ischemic stroke risk when added to standard...
J&J halts anti‑tau study — posdinemab fails to slow decline
Johnson & Johnson terminated a mid‑stage trial of its anti‑tau monoclonal antibody posdinemab after an interim look showed the drug would not outperform placebo on clinical decline measures. The...
FDA probes Takeda’s Adzynma after pediatric death; neutralizing antibodies flagged
The U.S. Food and Drug Administration opened an investigation into Takeda’s engineered enzyme therapy Adzynma following reports that patients developed neutralizing antibodies and after a...
NervGen reports durable functional gains — CONNECT SCI data expand hope
NervGen Pharma released expanded CONNECT SCI data showing durable and broad functional improvements in people with chronic spinal cord injury treated with NVG‑291. The company presented week‑16...
Tempus buys OneOme’s PGx assets — consolidation in pharmacogenetics
Tempus confirmed the acquisition of the pharmacogenetics assets of OneOme, the Mayo Clinic spinoff that abruptly ceased operations in November. The deal transfers OneOme’s RightMed PGx test and...
Cellarity’s AI flags DILI — transcriptomics model posts high performance
Cellarity published a toxicogenomics resource and an AI model, ToxPredictor, designed to predict drug‑induced liver injury (DILI) using transcriptomic signatures from primary human hepatocytes....
Biogen pays $50M for Dayra’s oral macrocycles — Versant-backed startup launches
Biogen struck a collaboration with Versant‑backed Dayra Therapeutics, paying $50 million upfront to identify and optimize oral macrocyclic peptide candidates for immunological targets, with...
AlphaFold at five: Jumper outlines limits and next steps
Five years after AlphaFold 2 transformed protein structure prediction, co‑developer John Jumper reflected on its scientific impact and future directions. DeepMind’s AlphaFold family—now including...
Plasmidsaurus’ $50 RNA‑seq service rattles cores — speed and price disrupt
Plasmidsaurus launched a low‑cost, fast turnaround transcriptome service offering shallow‑depth RNA‑seq for $50 per academic sample and a promised 2–3 day turnaround, drawing strong demand and...
Bayer’s asundexian cuts stroke risk – Phase 3 rebound for FXIa inhibitors
Bayer reported a positive Phase 3 result showing its oral factor XIa inhibitor asundexian significantly reduced the risk of recurrent stroke in a late-stage trial. The readout reignites interest...
J&J halts anti‑tau posdinemab – Phase 2 stops as efficacy misses
Johnson & Johnson stopped a mid‑stage trial of its anti‑tau antibody posdinemab after an interim review found the drug did not slow clinical decline versus placebo. The company said it will...
Novo Nordisk’s semaglutide misses in Alzheimer’s trials – Two large studies negative
Novo Nordisk reported that two large placebo‑controlled trials of semaglutide failed to slow cognitive decline in patients with Alzheimer’s disease. The oral GLP‑1 agonist did not meet primary...
NervGen’s NVG‑291 shows durable gains – Expanded CONNECT SCI data reported
NervGen published expanded CONNECT SCI study data showing sustained, clinically meaningful improvements in function, independence, and quality of life for people with chronic spinal cord injury...